89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma.
Strontium plasma clearance is an important factor determining the absorbed dose to metastases and bone marrow in patients receiving 89Sr radionuclide therapy for metastatic bone disease. Amongst male patients with disseminated prostatic carcinoma, the renal component of strontium clearance is frequently greatly reduced compared with values reported for healthy middle aged men. We report a study of renal and gut strontium plasma clearance, renal function, calcium urinary excretion, parathyroid function and extent of skeletal osteoblastic metastatic disease in patients referred for radiostrontium therapy for metastasised prostatic malignancy. The wide variation in net strontium clearance was principally due to variation in the renal component. Low values of strontium renal clearance were found to correlate with the elevation of serum PTH and nephrogenous cyclic AMP, which in turn correlated with extent of skeletal metastatic disease. This suggests that the osteosclerotic metastases characteristic of prostatic carcinoma induce secondary hyperparathyroidism due to the high avidity of the skeleton for calcium. The resulting reduction in strontium excretion may be beneficial to the objectives of radiostrontium therapy.
Blake
G M
GM
Department of Nuclear Medicine, Southampton General Hospital, UK.
Wood
J F
JF
Wood
P J
PJ
Zivanovic
M A
MA
Lewington
V J
VJ
D001859:Bone Neoplasms / Q000378:metabolism / Q000556:secondary; D002118:Calcium / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D013326:Strontium Radioisotopes / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*
D010281:Parathyroid Hormone; D013326:Strontium Radioisotopes; D000242:Cyclic AMP; D002118:Calcium